REGN7508
Sponsors
Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals
Conditions
Atrial Fibrillation (AF)Cancer-Associated Thrombosis (CAT)Healthy VolunteersPeripheral Artery Disease (PAD)Symptomatic Venous Thromboembolism (VTE)Thromboembolic diseaseVenous ThromboembolismVenous Thromboembolism (VTE)
Phase 1
Phase 2
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Active, not recruitingNCT06299111
Start: 2024-09-20End: 2026-06-01Updated: 2026-01-12
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
CompletedCTIS2023-508602-14-00
Start: 2024-06-27End: 2025-01-08Target: 180Updated: 2024-09-30
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
CompletedNCT06454630
Start: 2024-06-27End: 2025-01-21Updated: 2026-03-02
A Master Protocol for a Phase 2 Randomized, Double-blind, Placebo-controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies against Factor XI for Prevention of Venous Thromboembolism in Patients with a Peripherally Inserted Central Catheter (ROXI-CATH).
RecruitingCTIS2023-508603-21-00
Start: 2024-09-20Target: 93Updated: 2026-01-26
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
RecruitingNCT07175428
Start: 2025-10-20End: 2027-04-21Target: 1200Updated: 2026-03-18
Phase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
RecruitingNCT07015905
Start: 2025-06-25End: 2027-05-12Target: 2000Updated: 2026-03-09
A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX).
RecruitingCTIS2025-520478-20-00
Start: 2025-11-05Target: 1067Updated: 2026-01-23
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
RecruitingNCT07213778
Start: 2025-11-24End: 2027-07-16Target: 2000Updated: 2026-03-18
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Not yet recruitingNCT07318610
Start: 2026-03-31End: 2029-08-03Target: 7050Updated: 2026-01-06
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
RecruitingNCT07410117
Start: 2026-03-09End: 2030-05-06Target: 860Updated: 2026-03-18
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Not yet recruitingNCT07430956
Start: 2026-03-18End: 2029-06-26Target: 2628Updated: 2026-02-24
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Not yet recruitingNCT07493304
Start: 2026-04-07End: 2031-07-08Target: 1600Updated: 2026-03-25
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)
Not yet recruitingCTIS2025-520479-25-00
Target: 40Updated: 2026-04-01